Skye Bioscience has completed enrollment for its phase 2a trial of SBI-100, a cannabinoid receptor type 1 agonist being developed for patients with primary open-angle glaucoma or ocular hypertension, according to a company press release.
“We believe the rapid rate of enrollment of this phase 2a study is supported by our discussions with key opinion leaders who have noted that alternative new classes of IOP-lowering drugs are needed and are excited for the potential of a CB1 agonist developed for this clinical application,” Tu Diep, Skye’s chief development officer, said in